| 2025 |
| 01/10 | 1,530 | 1,536 | 1,507 | 1,510 | -1.69% | 8,082,200 | 2兆7325億 | -2.45% |
| 01/09 | 1,522 | 1,545 | 1,514 | 1,536 | +0.99% | 6,352,500 | 2兆7796億 | -0.97% |
| 01/09 | 8:30 IZERVAY(avacincaptad pegol) FDAがクラス1の一部変更承認の再申請を受理 |
| 01/08 | 1,532 | 1,541 | 1,521 | 1,521 | -1.04% | 4,685,800 | 2兆7524億 | -2% |
| 01/07 | 1,535 | 1,544 | 1,528 | 1,537 | +0.65% | 4,581,500 | 2兆7814億 | -1.09% |
| 01/06 | 1,535 | 1,537 | 1,517 | 1,527 | -0.52% | 7,168,100 | 2兆7633億 | -1.86% |
| 2024 |
| 12/30 | 1,549 | 1,551 | 1,533 | 1,535 | -0.65% | 5,159,600 | 2兆7778億 | -1.41% |
| 12/27 | 1,530 | 1,550 | 1,530 | 1,545 | +0.98% | 5,433,500 | 2兆7959億 | -0.9% |
| 12/26 | 1,517 | 1,530 | 1,517 | 1,530 | +0.59% | 4,790,900 | 2兆7687億 | -1.86% |
| 12/25 | 1,540 | 1,541 | 1,514 | 1,521 | -0.65% | 4,191,500 | 2兆7524億 | -2.56% |
| 12/24 | 1,525 | 1,535 | 1,516 | 1,531 | +0.79% | 3,981,100 | 2兆7705億 | -2.05% |
| 12/23 | 1,530 | 1,534 | 1,508 | 1,519 | -1.56% | 5,027,300 | 2兆7488億 | -2.88% |
| 12/20 | 1,528 | 1,545 | 1,526 | 1,543 | +1.51% | 9,307,400 | 2兆7923億 | -1.59% |
| 12/19 | 1,507 | 1,526 | 1,502 | 1,520 | +0.66% | 4,881,400 | 2兆7506億 | -3.37% |
| 12/18 | 1,510 | 1,517 | 1,505 | 1,510 | -0.46% | 5,961,800 | 2兆7325億 | -4.37% |
| 12/17 | 1,517 | 1,524 | 1,507 | 1,517 | -0.65% | 7,153,400 | 2兆7452億 | -4.35% |
| 12/16 | 1,553 | 1,556 | 1,522 | 1,527 | -1.93% | 5,263,800 | 2兆7633億 | -4.14% |
| 12/13 | 1,553 | 1,570 | 1,547 | 1,557 | -1.58% | 7,713,400 | 2兆8176億 | -2.81% |
| 12/12 | 1,576 | 1,589 | 1,574 | 1,582 | +0.44% | 4,357,900 | 2兆8628億 | -1.62% |
| 12/11 | 1,578 | 1,593 | 1,571 | 1,575 | -0.38% | 4,426,400 | 2兆8502億 | -2.42% |
| 12/10 | 1,599 | 1,600 | 1,575 | 1,581 | -0.13% | 3,738,500 | 2兆8610億 | -2.47% |
| 12/09 | 1,581 | 1,593 | 1,576 | 1,583 | +0.13% | 3,362,900 | 2兆8646億 | -2.7% |
| 12/06 | 1,591 | 1,596 | 1,576 | 1,581 | -0.75% | 3,658,200 | 2兆8610億 | -3.3% |
| 12/05 | 1,604 | 1,608 | 1,588 | 1,593 | -0.81% | 3,855,800 | 2兆8827億 | -3.04% |
| 12/04 | 1,607 | 1,609 | 1,595 | 1,606 | -0.86% | 4,088,400 | 2兆9063億 | -2.73% |
| 12/03 | 1,600 | 1,625 | 1,595 | 1,620 | +2.27% | 6,375,200 | 2兆9316億 | -2.29% |
| 12/02 | 1,570 | 1,589 | 1,564 | 1,584 | +1.41% | 4,225,100 | 2兆8665億 | -4.75% |
| 11/29 | 1,560 | 1,570 | 1,549 | 1,562 | -0.64% | 5,503,400 | 2兆8266億 | -6.41% |
| 11/28 | 1,563 | 1,574 | 1,555 | 1,572 | +0.32% | 3,743,400 | 2兆8447億 | -6.26% |
| 11/27 | 1,572 | 1,579 | 1,562 | 1,567 | -0.32% | 3,421,600 | 2兆8357億 | -7% |
| 11/26 | 1,568 | 1,572 | 1,553 | 1,572 | 0% | 4,036,300 | 2兆8447億 | -7.15% |
| 11/25 | 1,598 | 1,602 | 1,570 | 1,572 | +0.64% | 14,539,600 | 2兆8447億 | -7.64% |
| 11/22 | 1,575 | 1,578 | 1,559 | 1,562 | -0.64% | 5,561,900 | 2兆8266億 | -8.6% |
| 11/21 | 1,585 | 1,599 | 1,570 | 1,572 | -0.06% | 5,667,600 | 2兆8447億 | -8.39% |
| 11/20 | 1,574 | 1,581 | 1,562 | 1,573 | +0.77% | 4,935,500 | 2兆8466億 | -8.65% |
| 11/19 | 1,578 | 1,585 | 1,544 | 1,561 | -3.34% | 10,715,900 | 2兆8248億 | -9.66% |
| 11/19 | 8:00 IZERVAY(avacincaptad pegol)米国における一部変更承認申請に関する最新情報 |
| 11/18 | 1,656 | 1,660 | 1,612 | 1,615 | -3.35% | 6,837,200 | 2兆9226億 | -6.92% |
| 11/15 | 1,673 | 1,692 | 1,669 | 1,671 | +0.18% | 7,002,400 | 3兆239億 | -4.08% |
| 11/14 | 1,685 | 1,687 | 1,668 | 1,668 | -0.12% | 4,814,200 | 3兆185億 | -4.41% |
| 11/13 | 1,705 | 1,707 | 1,664 | 1,670 | -2.34% | 8,468,300 | 3兆221億 | -4.46% |
| 11/12 | 1,739 | 1,747 | 1,702 | 1,710 | -1.16% | 5,805,800 | 3兆945億 | -2.34% |
| 11/11 | 1,716 | 1,731 | 1,711 | 1,730 | +0.82% | 3,854,100 | 3兆1307億 | -1.26% |
| 11/08 | 1,752 | 1,753 | 1,713 | 1,716 | -1.1% | 4,949,800 | 3兆1053億 | -2.05% |
| 11/07 | 1,735 | 1,745 | 1,713 | 1,735 | -0.46% | 6,292,000 | 3兆1397億 | -0.86% |
| 11/06 | 1,735 | 1,775 | 1,732 | 1,743 | +0.81% | 5,983,900 | 3兆1542億 | -0.29% |
| 11/05 | 1,700 | 1,748 | 1,700 | 1,729 | -2.97% | 7,318,000 | 3兆1289億 | -0.86% |
| 11/01 | 1,770 | 1,797 | 1,762 | 1,782 | -0.78% | 4,864,900 | 3兆2248億 | +2.24% |
| 10/31 | 1,809 | 1,811 | 1,764 | 1,796 | +0.39% | 10,152,700 | 3兆2501億 | +3.16% |
| 10/30 | 15:00 為替差損の計上について |
| 10/30 | 15:00 2025年3月期第2四半期(中間期)決算補足資料 |
| 10/30 | 15:00 2025年3月期第2四半期(中間期)決算説明会資料 |
| 10/30 | 15:00 2025年3月期第2四半期(中間期)決算短信[IFRS](連結) |
| 10/30 | 1,790 | 1,803 | 1,780 | 1,789 | -0.11% | 11,665,600 | 3兆2374億 | +2.93% |
| 10/29 | 1,748 | 1,792 | 1,741 | 1,791 | +3.17% | 6,313,800 | 3兆2411億 | +3.17% |
| 10/28 | 1,697 | 1,749 | 1,693 | 1,736 | -0.06% | 5,818,600 | 3兆1415億 | +0.12% |
| 10/28 | 8:00 avacincaptad pegol(ACP)欧州における販売承認申請に関する最新情報 |
| 10/25 | 1,758 | 1,760 | 1,728 | 1,737 | -1.36% | 2,757,500 | 3兆1433億 | +0.17% |
| 10/24 | 1,763 | 1,774 | 1,758 | 1,761 | -0.06% | 4,069,200 | 3兆1868億 | +1.67% |
| 10/23 | 1,768 | 1,783 | 1,759 | 1,762 | -0.9% | 3,248,600 | 3兆1886億 | +1.85% |
| 10/22 | 1,786 | 1,786 | 1,760 | 1,778 | -0.39% | 3,554,900 | 3兆2175億 | +2.95% |
| 10/21 | 1,762 | 1,788 | 1,755 | 1,785 | +1.31% | 4,305,000 | 3兆2302億 | +3.3% |
| 10/21 | 8:30 VYLOY(ゾルベツキシマブ(遺伝子組換え))局所進行性または転移性胃腺がんおよび食道胃接合部腺がんの治療薬として米国で承認取得 |
| 10/18 | 1,750 | 1,772 | 1,745 | 1,762 | +1.67% | 3,711,700 | 3兆1886億 | +1.97% |
| 10/17 | 1,724 | 1,741 | 1,717 | 1,733 | +1.29% | 4,528,300 | 3兆1361億 | +0.23% |
| 10/16 | 1,710 | 1,732 | 1,695 | 1,711 | -0.87% | 3,780,500 | 3兆963億 | -1.21% |
| 10/15 | 1,748 | 1,757 | 1,724 | 1,726 | -1.43% | 4,950,300 | 3兆1234億 | -0.58% |
| 10/11 | 1,744 | 1,754 | 1,739 | 1,751 | -0.85% | 5,450,600 | 3兆1687億 | +0.75% |
| 10/10 | 1,761 | 1,771 | 1,750 | 1,766 | +1.09% | 2,951,800 | 3兆1958億 | +1.49% |
| 10/09 | 1,760 | 1,762 | 1,727 | 1,747 | +0.17% | 3,475,600 | 3兆1614億 | +0.29% |
| 10/08 | 1,747 | 1,751 | 1,718 | 1,744 | -0.85% | 5,461,400 | 3兆1560億 | 0% |
| 10/07 | 1,747 | 1,767 | 1,729 | 1,759 | +1.79% | 5,004,100 | 3兆1831億 | +0.69% |
| 10/04 | 1,720 | 1,730 | 1,715 | 1,728 | +0.29% | 3,360,400 | 3兆1270億 | -1.26% |
| 10/03 | 1,707 | 1,729 | 1,705 | 1,723 | +2.56% | 4,579,600 | 3兆1180億 | -1.71% |
| 10/02 | 1,667 | 1,680 | 1,659 | 1,680 | +0.18% | 4,378,600 | 3兆402億 | -4.38% |
| 10/01 | 1,650 | 1,677 | 1,646 | 1,677 | +1.82% | 4,448,400 | 3兆348億 | -4.82% |
| 09/30 | 1,650 | 1,653 | 1,621 | 1,647 | -3.68% | 8,602,100 | 2兆9805億 | -6.84% |
| 09/27 | 1,690 | 1,711 | 1,670 | 1,710 | -0.52% | 7,305,000 | 3兆945億 | -3.66% |
| 09/26 | 1,729 | 1,733 | 1,704 | 1,719 | -1.21% | 9,414,000 | 3兆1108億 | -3.21% |
| 09/25 | 1,740 | 1,746 | 1,726 | 1,740 | +0.93% | 5,364,000 | 3兆1488億 | -2.03% |
| 09/24 | 15:00 抗体ー薬物複合体パドセブ根治切除不能な尿路上皮癌に対する一次治療としてのペムブロリズマブとの併用療法について日本で適応追加に関する承認を取得 |
| 09/24 | 1,750 | 1,759 | 1,724 | 1,724 | -0.75% | 5,755,300 | 3兆1198億 | -2.82% |
| 09/24 | 8:30 VYLOY(ゾルベツキシマブ)局所進行性または転移性胃腺がんおよび食道胃接合部腺がんに対する化学療法との併用として欧州で承認取得 |
| 09/20 | 1,750 | 1,758 | 1,731 | 1,737 | +0.29% | 7,208,300 | 3兆1433億 | -2.03% |
| 09/19 | 1,743 | 1,762 | 1,717 | 1,732 | +1.29% | 5,966,700 | 3兆1343億 | -2.26% |
| 09/18 | 1,696 | 1,720 | 1,690 | 1,710 | +1.24% | 5,122,200 | 3兆945億 | -3.39% |
| 09/17 | 1,718 | 1,721 | 1,644 | 1,689 | -0.94% | 13,870,600 | 3兆565億 | -4.41% |
| 09/13 | 1,785 | 1,805 | 1,699 | 1,705 | -4.75% | 11,212,800 | 3兆854億 | -3.4% |
| 09/12 | 1,789 | 1,815 | 1,786 | 1,790 | +0.62% | 4,828,500 | 3兆2392億 | +1.47% |
| 09/11 | 1,800 | 1,805 | 1,769 | 1,779 | -0.67% | 4,952,100 | 3兆2193億 | +1.08% |
| 09/10 | 1,820 | 1,825 | 1,789 | 1,791 | -1.32% | 6,105,700 | 3兆2411億 | +2.11% |
| 09/09 | 1,788 | 1,820 | 1,773 | 1,815 | +0.78% | 4,246,500 | 3兆2845億 | +3.83% |
| 09/06 | 1,795 | 1,814 | 1,795 | 1,801 | +0.33% | 4,454,300 | 3兆2592億 | +3.21% |
| 09/05 | 1,762 | 1,802 | 1,756 | 1,795 | -0.22% | 4,682,700 | 3兆2483億 | +3.1% |
| 09/04 | 1,773 | 1,799 | 1,769 | 1,799 | -1.15% | 5,693,000 | 3兆2555億 | +3.39% |
| 09/03 | 15:00 無担保普通社債発行に関するお知らせ |
| 09/03 | 1,790 | 1,822 | 1,786 | 1,820 | +1.56% | 3,609,200 | 3兆2935億 | +4.78% |
| 09/02 | 1,820 | 1,820 | 1,783 | 1,792 | -1.38% | 3,628,200 | 3兆2429億 | +3.46% |
| 08/30 | 1,820 | 1,826 | 1,801 | 1,817 | -0.6% | 7,693,800 | 3兆2881億 | +5.15% |
| 08/29 | 1,819 | 1,835 | 1,815 | 1,828 | +0.72% | 5,467,400 | 3兆3080億 | +6.16% |
| 08/28 | 1,810 | 1,821 | 1,796 | 1,815 | -0.06% | 4,352,200 | 3兆2845億 | +5.77% |
| 08/28 | 8:30 抗体ー薬物複合体PADCEV(エンホルツマブベドチン)進行性尿路上皮がん患者の一次治療を対象としたペムブロリズマブとの併用療法について欧州で承認を取得 |
| 08/27 | 1,794 | 1,817 | 1,790 | 1,816 | +1.17% | 4,172,900 | 3兆2863億 | +6.26% |
| 08/26 | 1,793 | 1,802 | 1,774 | 1,795 | -1.81% | 4,282,200 | 3兆2483億 | +5.46% |
| 08/23 | 1,816 | 1,828 | 1,807 | 1,828 | +0.66% | 6,488,600 | 3兆3080億 | +7.78% |
| 08/22 | 1,760 | 1,816 | 1,752 | 1,816 | +3.77% | 11,372,000 | 3兆2863億 | +7.39% |
| 08/21 | 1,730 | 1,760 | 1,727 | 1,750 | +2.22% | 8,680,300 | 3兆1669億 | +3.86% |
| 08/20 | 1,712 | 1,725 | 1,703 | 1,712 | +1.66% | 5,587,100 | 3兆981億 | +1.78% |
| 08/20 | 8:30 抗体ー薬物複合体PADCEV(エンホルツマブベドチン)中国で承認を取得 |
| 08/19 | 1,716 | 1,716 | 1,678 | 1,684 | -1.86% | 5,475,600 | 3兆474億 | +0.3% |
| 08/16 | 1,723 | 1,724 | 1,700 | 1,716 | +1.18% | 5,322,000 | 3兆1053億 | +2.2% |
| 08/15 | 1,674 | 1,701 | 1,669 | 1,696 | +1.01% | 4,777,000 | 3兆691億 | +1.25% |
| 08/14 | 1,671 | 1,680 | 1,643 | 1,679 | +1.76% | 6,432,600 | 3兆384億 | +0.42% |
